Lymphocyte Biology Is Driving a More Precise Model of Autoimmune Disease
Autoimmune disease is increasingly being framed as a disorder of broken tolerance, aberrant lymphocyte activation, and organ-specific immune programming rather than a single uniform inflammatory state. This editorial for the Research Topic Lymphocytes and autoimmune disease: from molecular mechanism to clinical implications gathers 16 contributions that move from molecular pathology to translational biomarkers and targeted intervention. The range is wide, but the message is remarkably consistent: immune phenotypes alone are no longer enough. Mechanism-based stratification is becoming the central clinical goal.
A quiet but important shift runs through the collection. Biomarkers are no longer being treated as static readouts of inflammation; they are being tested as tools for diagnosis, treatment selection, and risk prediction in specific diseases and even specific organ compartments.
Biomarkers Are Being Pulled Closer to the Bedside
Several contributions focus on markers that could help clinicians separate active disease from background immune noise. Wu and colleagues reviewed the systemic immune-inflammation index across rheumatoid arthritis, systemic lupus erythematosus, spondyloarthritis, and vasculitis, finding consistent links with disease activity, treatment response, and organ involvement. The practical challenge is calibration. Because disease biology differs across these disorders, a single threshold is unlikely to perform well in every setting, and disease-specific reference cutoffs remain necessary before SII can be used with confidence in routine care.
Zinellu and colleagues extended the biomarker discussion to soluble CD40 ligand and soluble CD40. Their meta-analysis showed higher circulating levels in rheumatic diseases than in controls, while sCD40 rose further in active disease. The biology is intuitive: the CD40 pathway sits at the center of B-cell and antigen-presenting cell activation, so increased circulating signal fits with ongoing immune escalation. Yet these markers cannot be interpreted in isolation, because infection and malignancy can also alter them.
One sentence captures the clinical constraint clearly: immune biomarkers are only as useful as their specificity.
Disease-Specific Immune Signatures Are Replacing Broad Inflammation Markers
The most compelling translational work in this collection is not about generic inflammation at all. Guo and colleagues identified elevated CD38+CD4+ T cells and CD38+CD8+ T cells in anti-MDA5-positive dermatomyositis. Those cells correlated with interferon-α and predicted interstitial lung disease and rapidly progressive interstitial lung disease by ROC analysis. The signal is biologically coherent. Interferon-driven cytotoxic T-cell activation is deeply tied to the aggressive pulmonary phenotype seen in this subgroup, and a blood-based marker that tracks that axis could help identify patients who need urgent escalation.
Zhang and colleagues showed that absolute T-lymphocyte subset monitoring helped distinguish myelodysplastic syndrome with pure red cell aplasia and guided immunosuppressive therapy. Although the condition is hematologic rather than rheumatologic, the lesson travels well: lymphocyte quantification can clarify diagnosis when marrow failure and immune dysregulation overlap.
In pemphigus vulgaris, Zhou and colleagues reported that persistent anti-Dsg1 positivity after remission was associated with cataracts, while higher baseline anti-Dsg3 titers and PDAI scores predicted sustained anti-Dsg3 positivity. A cutoff of 157.4 U/mL was identified for anti-Dsg3. This kind of serologic persistence matters because it exposes a familiar clinical mismatch: skin or mucosal healing can occur while autoantibody activity remains detectable, and that discordance complicates decisions about tapering treatment or forecasting relapse.
B-Cell and T-Cell Abnormalities Are Being Mapped by Organ Site
The collection repeatedly returns to a central point: lymphocyte dysfunction is not abstract. It is tissue-shaped. In Sjögren’s syndrome, CD4+ T-cell infiltration and B-cell hyperactivation with plasmablast and plasma-cell expansion track with disease activity. In systemic lupus erythematosus, organ-specific B-cell abnormalities are more granular still: impaired early B-cell development in bone marrow, reduced regulatory B cells, increased atypical B cells and double-negative B cells in blood, atypical memory B cells and long-lived plasma cells in kidney, BAFF-driven skin lesions, and BAFF, APRIL, and proBDNF linked to neuropsychiatric involvement.
That level of compartmentalization has direct implications for therapy. Broad immunosuppression may calm systemic inflammation while leaving the dominant pathogenic compartment relatively untouched. Target selection is becoming as important as drug selection.
Su and colleagues added a striking example from type 1 diabetes. Gut-tropic α4β7+CD8+ T cells were reduced in blood but enriched in pancreatic islets, where they showed increased cytokine production and beta-cell cytotoxicity. The cells were shaped by inflammatory cytokines and altered by α4β7 blockade. This is a vivid illustration of trafficking biology: the destructive lymphocyte population may be sparse in circulation but concentrated at the disease site, which means blood tests can underestimate tissue injury unless homing pathways are considered.
Metabolism, RNA Control, and Post-Translational Change Are Rewriting Mechanistic Explanations
The mechanistic papers in this topic move beyond receptor-ligand interactions and into the intracellular machinery that governs immune fate. Lande and colleagues showed that citrullination and carbamylation of LL37 direct different autoreactive T-cell polarization in psoriasis. Native and carbamylated LL37-specific T cells were Th1/Th17-like, while citrullinated LL37-specific T cells were Tfh-like. Post-translational modification is doing more than creating antigenic novelty; it is steering T-cell lineage choice.
Fattahi and colleagues identified HuR as a direct RNA-binding protein that stabilizes Foxp3 mRNA. When HuR was deleted, Foxp3 half-life shortened, Treg suppressive capacity fell, lymphocyte infiltration spread across multiple organs, and the Foxp3–Rorc/Treg–Th17 axis was disrupted. The biological logic is strong. Regulatory T cells depend on durable Foxp3 expression; remove that stability and immune restraint collapses.
Metabolic signaling appears just as important. The review of SGLT2 inhibitors in autoimmune disease describes suppression of T-cell proliferation and activation, inhibition of glycolysis and mTORC1/c-Myc signaling, and reduction of NLRP3 inflammasome activity. In lupus nephritis and IgA nephropathy, renal signals are already pointing toward a dual metabolic and anti-inflammatory effect. These agents are being reconsidered not simply as glucose-lowering drugs, but as immunometabolic modulators with cardiorenal relevance.
New Therapeutic Concepts Are Emerging, but Translation Will Depend on Specificity and Safety
Among the therapeutic reports, the real-world cohort of treatment-naïve patients with moderate-to-severe SLE stands out. First-line rituximab achieved higher rates of mLLDAS and remission at 12 months than conventional immunosuppressants, with comparable major infection rates. For a disease in which delayed control can translate into cumulative organ damage, early B-cell depletion is an especially consequential strategy. The result supports the idea that earlier intervention against B-cell–driven autoimmunity may outperform stepwise escalation in selected patients.
Gardell and colleagues introduced MTX-101, a bispecific antibody targeting inhibitory KIR and CD8, designed to restore CD8 Treg function and selectively deplete pathogenic CD4+ T cells. In organoid models of celiac disease and Crohn’s disease, it reduced antigen-induced epithelial death, and in a humanized graft-versus-host disease mouse model it delayed disease without broad immune activation. The appeal is obvious. A therapy that separates pathogenic from protective immunity could solve one of the oldest problems in autoimmune medicine. The remaining barrier is proving that this selectivity holds in patients over time.
FAP-targeted imaging and therapy in rheumatoid arthritis represent a different route toward precision care. Fibroblast activation protein is overexpressed on activated fibroblast-like synoviocytes, allowing FAPI PET/CT to visualize synovitis and extra-articular fibrosis, while FAP-directed photodynamic or radionuclide therapy may deplete pathogenic fibroblasts. Yet specificity is imperfect because FAP is also expressed in osteoarthritis and other benign lesions. Dual-tracer PET/CT, dual-target probes, and AI-based radiomics are being proposed to improve lesion discrimination, but imaging that sees too much biology can create its own diagnostic ambiguity.
The Next Phase Will Demand Standardization, Not Just Discovery
The editorial closes on a practical agenda: biomarker research must move from measurable to actionable, with prospective validation and standardized cutoffs for SII, sCD40/sCD40L, CD38+ T-cell signatures, and autoantibody kinetics. Composite endpoints such as mLLDAS and DORIS remission need to be harmonized with organ damage, patient-reported outcomes, infection risk, and malignancy risk. Spatial and single-cell multi-omics will be necessary to connect blood signatures to tissue disease, and functional validation in organoids and humanized models will need to keep pace with discovery.
For autoimmune medicine, the field is no longer asking whether lymphocytes matter. It is asking which lymphocyte program matters in which tissue, at what time, and with what measurable consequence for treatment choice.